ZN-A-1041 is named as an intervention in 2 current clinical trials in our UK, USA and China registers. 1 is recruiting patients now. The most common phase is Phase 1/2. The lead sponsor is Hoffmann-La Roche. The most-studied condition is HER2-positive Breast Cancer.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
NCT07413939 · ClinicalTrials.gov ↗ · HER2-positive Breast Cancer
|
Phase 2/3 | Recruiting | Hoffmann-La Roche | UK, USA, China |
|
A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors
NCT05593094 · ClinicalTrials.gov ↗ · Advanced Solid Tumors, HER2-positive Breast Cancer
|
Phase 1/2 | Active, closed | Hoffmann-La Roche | UK, USA |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Hoffmann-La Roche | 2 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in UK | 2 | 1 |
| Clinical trials in USA | 2 | 1 |
| Clinical trials in China | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our UK, USA and China registers name ZN-A-1041 (also registered as RO7771950) as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 1 of the 2 trials is recruiting: 1 with sites in UK, 1 with sites in USA and 1 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
The lead sponsor is Hoffmann-La Roche. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how ZN-A-1041 works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how ZN-A-1041 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists ZN-A-1041 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.